Debby Kruijsen began her career in antibody discovery in 2011 when she obtained a PhD in immunology at the University of Utrecht, The Netherlands, studying the role of antibodies in affecting antigen presentation and subsequent Respiratory Syncytial Virus specific T cell activation. Her interest in immune modulating activities and potential of antibodies led her to work at ModiQuest Research as a Scientist supervising hybridoma antibody discovery projects in 2012—the same year ModiQuest Research moved its laboratories and offices from Nijmegen to Oss and Debby and her colleagues became part of the Pivot Park community. A year later, she was promoted to Head Contract Research where she was responsible for all contract research projects and business development.
ModiQuest Research was acquired by ImmunoPrecise Antibodies Ltd in April 2018, which allows further growth and development to operate globally and offer antibody services from target analysis to pre-clinical studies. Debby shares, “It is great to see the growth of the company during the last years to a full-service, therapeutic antibody discovery company serving clients with complex therapeutic antibody needs in a diverse range of disease areas.” Most recently, Debby was appointed as the General Manager of ModiQuest Research following the resignation of Jos Raats, founder and former Managing Director of ModiQuest Research. Jos left to pursue his duties as CEO of Absano BV, a company developing antibodies for therapeutic and diagnostic applications in the field of cancer, autoimmunity, and infection, along with TACPA B.V., a clinical stage company focusing on a phase I anti-inflammatory antibody candidate directed at multiple diseases.
Related news
Ongoing expansion of Acerta Pharma’s discovery and clinical operations in Oss
Acerta Pharma is one of the most successful pharmaceutical companies at Pivot Park. The discovery team has recently doubled in...
View article
“I liked academic work, but after my PhD I did not aspire to an academic career: I wanted to broaden my horizons.”
BioConnection, a spin-off of MSD/Organon, has undergone rapid development in recent years: from a consultant/broker without its own facilities to a production company that offers its Drug Product related services to medium-sized pharmaceutical players worldwide. The core business is the filling of medicines in various forms under GMP, mostly in vials and syringes. BioConnection works for customers at Pivot Park, but also globally for pharmaceutical companies in, amongst others, US, Europe, Australia, Brazil, Israel, , Korea and Taiwan.
View article
Glycostem’s mission to manufacture NK cells from cord blood stem cells and treat cancer patients could play a pivotal role in combating this deadly disease.
Glycostem develops innovative therapies for the treatment of different types of cancer: leukaemia, lymphoma and solid cancers. It is an off-the-shelf immune therapy, in which so-called Natural Killer Cells play an important role. John Veluchamy focuses on the development of affordable, highly effective, off-the-shelf therapy against tumours. His research into NK cells, derived from the umbilical cord, plays an important role in this. Veluchamy comes from India, studied Biomedical and Molecular Sciences at King’s College in London and obtained his PhD in NK cell immunotherapy from VU University Amsterdam in 2018. He has been working full time at Glycostem since December 2016. Veluchamy sees a major role for the Netherlands in the development of new medicines. The arrival of the European Medical Agency will consolidate this role.
View article